Liang Y, Meng Z, Ding XL, Jiang M. Effects of proton pump inhibitors on inflammatory bowel disease: An updated review. World J Gastroenterol 2024; 30(21): 2751-2762 [PMID: 38899331 DOI: 10.3748/wjg.v30.i21.2751]
Corresponding Author of This Article
Man Jiang, PharmD, Chief Pharmacist, Director, Professor, Department of Pharmacy, The Affiliated Hospital of Qingdao University, No. 16 Jiangsu Road, Qingdao 266003, Shandong Province, China. jasmanouc@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jun 7, 2024; 30(21): 2751-2762 Published online Jun 7, 2024. doi: 10.3748/wjg.v30.i21.2751
Effects of proton pump inhibitors on inflammatory bowel disease: An updated review
Yu Liang, Zhen Meng, Xue-Li Ding, Man Jiang
Yu Liang, Man Jiang, Department of Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao 266003, Shandong Province, China
Zhen Meng, Department of Intervention, The Affiliated Hospital of Qingdao University, Qingdao 266003, Shandong Province, China
Xue-Li Ding, Department of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao 266003, Shandong Province, China
Author contributions: Jiang M designed the study; Liang Y drafted the manuscript; Meng Z drew the pictures; Jiang M and Ding XL revised the manuscript; and all authors have read and approve the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Man Jiang, PharmD, Chief Pharmacist, Director, Professor, Department of Pharmacy, The Affiliated Hospital of Qingdao University, No. 16 Jiangsu Road, Qingdao 266003, Shandong Province, China. jasmanouc@163.com
Received: February 2, 2024 Revised: April 26, 2024 Accepted: May 15, 2024 Published online: June 7, 2024 Processing time: 121 Days and 23.5 Hours
Abstract
Inflammatory bowel disease (IBD) is believed to be caused by various factors, including abnormalities in disease susceptibility genes, environmental factors, immune factors, and intestinal bacteria. Proton pump inhibitors (PPIs) are the primary drugs used to treat acid-related diseases. They are also commonly prescribed to patients with IBD. Recent studies have suggested a potential association between the use of certain medications, such as PPIs, and the occurrence and progression of IBD. In this review, we summarize the potential impact of PPIs on IBD and analyze the underlying mechanisms. Our findings may provide insights for conducting further investigations into the effects of PPIs on IBD and serve as an important reminder for physicians to exercise caution when prescribing PPIs to patients with IBD.
Core Tip: Inflammatory bowel disease (IBD) can be induced by multiple factors. Incidentally, several drugs, including proton pump inhibitors (PPIs), may also be involved in the occurrence and development of IBD. This study is an updated review of the literature. It summarizes the potential impact of PPIs on the risk, severity, and pharmacotherapy of IBD and analyzes the possible mechanisms through which PPIs may contribute to the development of IBD.
